Vedanta Biosciences (VE202 microbiome) Overview
- Status
- Acquired/Merged
- Latest Deal Type
- Asset Purch.
- Financing Rounds
- 1
Vedanta Biosciences (VE202 microbiome) General Information
Description
Bacterial product meant to treat inflammatory bowel diseases. The microbiome pharmaceutical candidate, VE202, is a mix of bacteria from the Clostridia subspecies that could be a treatment for Crohn's disease and ulcerative colitis. It will will help either replenish or rejuvenate a type of immune cell called regulatory T-cells, which help the body cool off inflammation.
Contact Information
- Boston, MA
- United States
Vedanta Biosciences (VE202 microbiome) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Vedanta Biosciences (VE202 microbiome)‘s full profile, request access.
Request a free trialVedanta Biosciences (VE202 microbiome) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Vedanta Biosciences (VE202 microbiome)‘s full profile, request access.
Request a free trial